Loading...
NPI 1700280971 · Minneapolis, MN · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Premier Biotech Labs, LLC is a clinical medical laboratory provider located in Minneapolis, Minnesota. This profile covers 5 Medicare and 37 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Premier Biotech Labs, LLC |
| Address | 723 Kasota Ave Se |
| City | Minneapolis |
| State | MN |
| ZIP | 55414 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | October 17, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicaid | $41.4M |
| Medicare | $416.7K |
Service line and code mix indicate PREMIER BIOTECH LABS, LLC operates primarily as a high-throughput clinical toxicology/drug-testing laboratory: the Medicare and Medicaid revenue lists are dominated by presumptive instrumented screens (80307) and definitive confirmatory tests (G0480, G0482) that reference GC/MS and LC/MS methods and specimen validity testing. This combination of codes signals the lab provides same-day presumptive screening plus multi-class confirmatory analyses rather than a broad clinical chemistry or pathology menu.
Payer mix is heavily skewed toward Medicaid: lifetime Medicaid revenue is $41.4M compared with Medicare revenue of $416.7K, so Medicaid is effectively the primary payer by scale for this provider. Analysts should treat the entity as a Medicaid-focused testing vendor when assessing network exposure and utilization patterns.
Revenue concentration on Medicare is very narrow: the precomputed top three Medicare codes account for 88.0% of the provider's Medicare revenue, with G0480 at 44.2%, 80307 at 36.6%, and G0481 at 7.2%. That concentration shows Medicare billing is almost entirely driven by a small set of drug-testing services rather than a diversified test portfolio.
Medicaid revenue is also concentrated in a few drug-testing codes: the top three Medicaid codes account for 79.2% of Medicaid revenue, specifically 80307 (31.8%), G0480 (27.6%), and G0482 (19.8%). The Medicaid income stream is therefore highly dependent on high-volume presumptive screening and confirmatory multi-class testing.
Competitive standing differs sharply by payer. In Medicaid the provider is a dominant in-state performer — 80307 ranks #2 of 101 providers in-state (99th percentile; extreme outlier), G0480 ranks #2 of 29 (96th percentile; extreme outlier), and G0482 ranks #1 of 13 (100th percentile; notably above typical) — indicating the lab is far above typical state volume for key drug-testing services and likely a market leader for Medicaid testing in Minnesota.
By contrast, its Medicare footprint shows notable but not exceptional national placement: 80307 ranks #90 of 4760 providers (98th percentile; typical, unremarkable volume for this code) and G0480 ranks #62 of 1590 providers (96th percentile; typical, unremarkable volume for this code), while G0481 sits lower at #403 of 1766 (77th percentile; typical, unremarkable volume for this code). These rankings suggest the lab has measurable national presence on select codes but is not an outlier on Medicare the way it is on Medicaid.
Operational scale is substantial on Medicaid claims volumes for top codes, reflecting true high throughput: reported claim counts include 366.3K claims for 80307, 163.3K claims for G0480, and 72.2K claims for G0482. Those raw counts, together with the $41.4M Medicaid revenue total, imply large daily specimen processing and billing operations and are relevant for capacity planning, contracting, and utilization management reviews.
Tenure and registry information: the NPI was enumerated on 2014-10-17 (~12 years ago), indicating the lab has been established long enough to scale repeatable Medicaid-centric workflows and relationships; this tenure supports the observed high Medicaid volumes rather than a short-term spike.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
5 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,640 | $110 | $184.1K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2,500 | $60 | $152.7K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 200 | $150 | $30K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 110 | $240 | $27.1K |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 120 | $200 | $22.8K |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 5 CPT/HCPCS codes.
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
37 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 366,250 | $40 | $13.2M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 163,350 | $70 | $11.4M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 72,160 | $110 | $8.2M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 32,790 | $130 | $4.3M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 43,560 | $90 | $4M |
| 80363 | The lab analyst measures the amount of or detects the presence of three or four opioids and opiate analogs, narcotic analgesics that depress the central nervous system, in the specimen. | 2,440 | $40 | $100K |
| 80346 | The lab analyst measures the amount of or detects the presence of one to twelve benzodiazepines, which are tranquilizers, in a patient specimen. | 8,520 | $10 | $51.1K |
| 80348 | The lab analyst measures the amount of or detects the presence of buprenorphine in a patient specimen. Buprenorphine is a drug used to treat opioid addiction, to control acute pain in individuals who… | 6,720 | $1 | $20.1K |
| 80362 | The lab analyst measures the amount of or detects the presence of one or two opioids and opiate analogs, narcotic analgesics that depress the central nervous system, in the specimen. | 5,090 | $1 | $15.3K |
| 80321 | The lab analyst detects and measures the alcohol biomarker in a patient specimen. Alcohol biomarkers are physiological indicators of the alcohol exposure or ingestion. In this test, the analyst tests… | 3,580 | $1 | $14.3K |
Showing 1–10 of 37
How this provider's Medicaid billing volume and revenue compare to other Minnesota providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Minnesota median
37 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 10 | 3,220 | $110 | $2.2M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1 | 10 | 2,200 | $120 | $1.3M |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 10 | 1,590 | $100 | $1.2M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2 | 30 | 340 | $60 | $890.4K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2 | 100 | 510 | $40 | $560.8K |
| 80361 | The lab analyst measures the amount of or detects the presence of one or more opiates, narcotic analgesics that depress the central nervous system, in the specimen. | 2 | 10 | 17,770 | $1 | $69.2K |
| 80348 | The lab analyst measures the amount of or detects the presence of buprenorphine in a patient specimen. Buprenorphine is a drug used to treat opioid addiction, to control acute pain in individuals who… | 2 | 10 | 6,720 | $1 | $54.8K |
| 80363 | The lab analyst measures the amount of or detects the presence of three or four opioids and opiate analogs, narcotic analgesics that depress the central nervous system, in the specimen. | 1 | 10 | 1,240 | $40 | $50.4K |
| 80353 | The lab analyst measures the amount of or detects the presence of cocaine in the patient specimen. | 2 | 10 | 3,720 | $1 | $42.2K |
| 80365 | The lab analyst measures the amount of or detects the presence of oxycodone, a synthetic opioid pain medication, in a patient specimen. | 2 | 10 | 3,500 | $1 | $38.5K |
Showing 1–10 of 37
Other providers in the same ZIP code as Premier Biotech Labs, LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.